Menu

 

Research News

Cancer drug shows promise for multiple sclerosis

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e7469 (Published 5 November 2012)
Cite this as: BMJ 2012;345:e7469

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Lancet 2012; doi:10.1016/S0140-6736(12)61611-0

Lancet 2012; doi:10.1016/S0140-6736(12)61768-1

Two manufacturer sponsored phase III trials suggest that alemtuzumab, an anti-CD52 monoclonal antibody that is licensed to treat leukaemia, may help control multiple sclerosis. Both trials lasted two years and compared alemtuzumab with interferon beta-1a, which is considered first line treatment. One trial looked at 563 patients who had not yet undergone treatment for multiple sclerosis, whereas the other trial looked at …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Subscribe

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

Latest comments and most commented

THIS WEEK'S POLL

Read related article

See previous polls